<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04125771</url>
  </required_header>
  <id_info>
    <org_study_id>Diclofenac potassium</org_study_id>
    <nct_id>NCT04125771</nct_id>
  </id_info>
  <brief_title>Diclofenac Potassium Alone Versus Diclofenac Potassium With Hyoscine-N-butyl Bromide (HBB in Endoscopy</brief_title>
  <official_title>Diclofenac Potassium Alone Versus Diclofenac Potassium With Hyoscine-N-butyl Bromide (HBB in Endoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aljazeera Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aljazeera Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diclofenac is a proven, commonly prescribed nonsteroidal anti-inflammatory drug (NSAID) that
      has analgesic, anti-inflammatory, and antipyretic properties, and has been shown to be
      effective in treating a variety of acute and chronic pain and inflammatory conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diclofenac is a proven, commonly prescribed nonsteroidal anti-inflammatory drug (NSAID) that
      has analgesic, anti-inflammatory, and antipyretic properties, and has been shown to be
      effective in treating a variety of acute and chronic pain and inflammatory conditions.

      . As with all NSAIDs, diclofenac exerts its action via inhibition of prostaglandin synthesis
      by inhibiting cyclooxygenase-1 (COX-1)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 25, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of women who will not feel pain</measure>
    <time_frame>within half an hour</time_frame>
    <description>the effect of medications on pain sensation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Diclofenac + HBB</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Women who will receive Diclofenac + HBB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenav + placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Women who will receive Diclofenav + placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diclofenac + HBB with hysteroscopy</intervention_name>
    <description>Giving Diclofenac + HBB with hysteroscopy</description>
    <arm_group_label>Diclofenac + HBB</arm_group_label>
    <arm_group_label>Diclofenav + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diclofenav + placebo</intervention_name>
    <description>Giving Diclofenac + placebo with hysteroscopy</description>
    <arm_group_label>Diclofenac + HBB</arm_group_label>
    <arm_group_label>Diclofenav + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Patients indicated for diagnostic hysteroscopy including infertility, bleeding,
             suspected intrauterine pathologies (eg polypi , septea) 2. Reproductive age 20 - 40yrs

        Exclusion Criteria:

          -  1. Menopausal and amenorrhic patients 2. Contraindication to office hysteroscopy such
             as:- pelvic inflammatory disease, marked cervical stenosis, pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female who will undergo hysteroscopy</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud Alalfy, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Algezeera hospitaland National Research Centre ,Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahmoud Alalfy, PhD</last_name>
    <phone>01002611058</phone>
    <email>mahmoudalalfy@ymail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Rashwan, MD</last_name>
    <phone>010o2611058</phone>
    <email>mahmoudalalfy@ymail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Algazeerah and Kasralainy hospital</name>
      <address>
        <city>Giza</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud Alalfy, master</last_name>
      <phone>+201002611058</phone>
      <email>mahmoudalalfy@ymail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ahmed Elgazzar, M.D</last_name>
      <phone>+201014005959</phone>
    </contact_backup>
    <investigator>
      <last_name>Mahmoud Alalfy, master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2019</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aljazeera Hospital</investigator_affiliation>
    <investigator_full_name>Mahmoud Alalfy</investigator_full_name>
    <investigator_title>Researcher , lecturer ,Obstetrics and Gynecology , National Research Centre</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

